Display options
Cite
Mallbris L, Davies J, Glasebrook A, et al. Molecular Insights into Fully Human and Humanized Monoclonal Antibodies: What are the Differences and Should Dermatologists Care?. J Clin Aesthet Dermatol. 2016;9(7):13-5
Mallbris, L., Davies, J., Glasebrook, A., Tang, Y., Glaesner, W., & Nickoloff, B. J. (2016). Molecular Insights into Fully Human and Humanized Monoclonal Antibodies: What are the Differences and Should Dermatologists Care?. The Journal of clinical and aesthetic dermatology, 9(7), 13-5.
Mallbris, Lotus, et al. "Molecular Insights into Fully Human and Humanized Monoclonal Antibodies: What are the Differences and Should Dermatologists Care?." The Journal of clinical and aesthetic dermatology vol. 9,7 (2016): 13-5.
Mallbris L, Davies J, Glasebrook A, Tang Y, Glaesner W, Nickoloff BJ. Molecular Insights into Fully Human and Humanized Monoclonal Antibodies: What are the Differences and Should Dermatologists Care?. J Clin Aesthet Dermatol. 2016 Jul;9(7):13-5. Epub 2016 Jul 01. PMID: 27672407; PMCID: PMC5022998.
Copy Download .nbib Format: NLM
Share it on

J Clin Aesthet Dermatol. 2016 Jul;9(7):13-5. Epub 2016 Jul 01.

Molecular Insights into Fully Human and Humanized Monoclonal Antibodies: What are the Differences and Should Dermatologists Care?.

The Journal of clinical and aesthetic dermatology

Lotus Mallbris, Julian Davies, Andrew Glasebrook, Ying Tang, Wolfgang Glaesner, Brian J Nickoloff

Affiliations

  1. Eli Lilly and Company, Indianapolis, Indiana.

PMID: 27672407 PMCID: PMC5022998

Abstract

In recent years, a large number of therapeutic monoclonal antibodies have come to market to treat a variety of conditions including patients with immune-mediated chronic inflammation. Distinguishing the relative clinical efficacy and safety profiles of one monoclonal antibody relative to another can be difficult and complex due to different clinical designs and paucity of head-to-head comparator studies. One distinguishing feature in interpreting clinical trial data by dermatologists may begin by determining whether a monoclonal antibody is fully human or humanized, which can be discerned by the generic name of the drug. Herein, this commentary highlights the distinctions and similarities of fully human and humanized monoclonal antibodies in their nomenclature, engineering, and clinical profiles. While there are a number of differences between these types of monoclonal antibodies, current evidence indicates that this designation does not impart any measurable impact on overall clinical efficacy and safety profiles of a given drug. Based on molecular insights provided in this commentary, it is clear that each monoclonal antibody, irrespective of being fully human or humanized, should be individually assessed for its clinical impact regarding safety and efficacy. Going beyond the type of generic name ascribed to a monoclonal antibody will be an ever-increasing theme for dermatologists as more therapeutic monoclonal antibodies emerge to potentially treat a wider scope of diseases with cutaneous manifestations.

References

  1. MAbs. 2010 May-Jun;2(3):256-65 - PubMed
  2. Annu Rev Biochem. 2007;76:1-22 - PubMed
  3. J Invest Dermatol. 2015 Jan;135(1):31-8 - PubMed
  4. Br J Dermatol. 2014 Feb;170(2):261-73 - PubMed
  5. MAbs. 2016;8(1):1-9 - PubMed
  6. Methods. 2005 May;36(1):3-10 - PubMed
  7. J Inflamm Res. 2016 Apr 19;9:39-50 - PubMed
  8. Curr Opin Immunol. 2016 Jun;40:62-9 - PubMed
  9. MAbs. 2011 May-Jun;3(3):243-52 - PubMed
  10. Curr Opin Struct Biol. 2016 Aug;39:79-88 - PubMed

Publication Types